Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
复制标题
DOI：
10.1007/s11864-016-0401-9
复制
发表时间：
2016-06
影响因子：
4.3
通讯作者：
Younes A
中科院分区：
文献类型：
--
作者：
Matsuki E;Younes A
复发性/难治性（R/R）霍奇金和非霍奇金淋巴瘤的治疗仍然具有挑战性。将利妥昔单抗引入B细胞非霍奇金淋巴瘤（B-NHL）治疗显著改善了患者的缓解率和生存率;然而，大约三分之一的弥漫性大B细胞淋巴瘤（最常见的B-NHL亚型）患者在一线治疗后仍有复发或变得难治。最近，抗体疗法和小分子抑制剂被批准用于治疗R/R淋巴瘤;这些药物包括维布妥昔单抗、伊曲替尼和艾代拉里斯。免疫检查点抑制剂和其他免疫疗法是新兴的治疗方法，目前正在各种临床试验中评估其对淋巴恶性肿瘤的疗效。在实体瘤中观察到这些治疗方式的惊人结果，并且证据正在积累以支持它们在各种淋巴瘤中的使用。免疫检查点抑制剂治疗的最令人兴奋的结果已经在R/R霍奇金淋巴瘤患者中看到，其中总体缓解率达到60- 80%。NHL的结果与其他实体恶性肿瘤的结果更相似，范围在20 - 40%之间，取决于组织学。目前正在等待这些药物的正式批准，以及检查点抑制剂和其他治疗方式（包括常规化疗，小分子抑制剂和其他免疫疗法）联合治疗的结果。虽然反应率很有希望，但必须注意管理独特的免疫相关不良事件，在某些情况下需要密切监测。使用肿瘤标本或外周血鉴定预测反应或严重不良事件的生物标志物将有助于选择适合这些类型治疗的患者以及确定免疫疗法领域内的理想治疗顺序。
Opinion statement Treatment for relapsed/refractory (R/R) Hodgkin and non-Hodgkin lymphoma remains challenging. The introduction of rituximab to B cell non-Hodgkin lymphoma (B-NHL) treatment significantly improved patients’ response rate and survival; however, approximately one third of patients with diffuse large B cell lymphoma, the most common B-NHL subtype, still have a relapse or become refractory after first-line therapy. More recently, antibody therapies and small-molecule inhibitors were approved for treating R/R lymphomas; these agents include brentuximab vedotin, ibrutinib, and idelalisib. Immune checkpoint inhibitors and other immune therapies are emerging treatments currently being evaluated in various clinical trials for their efficacy against lymphoid malignancies. Striking results from these treatment modalities have been observed in solid tumors, and evidence is accumulating to support their use in various lymphomas. The most exciting results from immune checkpoint inhibitor therapy have been seen in patients with R/R Hodgkin lymphoma, in whom the overall response rate has reached 60–80 %. Results in NHL are more similar to those seen in other solid malignancies, ranging between 20 and 40 %, depending on the histology. Formal approval of these drugs is being awaited, as are the results of combination therapy with checkpoint inhibitors and other treatment modalities, including conventional chemotherapy, small-molecule inhibitors, and other immune therapies. Although response rates have been promising, attention must be paid to the management of unique immune-related adverse events, which warrant close monitoring in some cases. Identification of biomarkers that predict response or severe adverse events using either the tumor specimen or peripheral blood would aid in selecting patients suited for these types of treatment as well as determining the ideal sequence of treatment within the realm of immune therapies.
登录
查看更多内容
影响因子：
20.3
作者：
Green, Michael R.;Monti, Stefano;Shipp, Margaret A.
通讯作者：
Shipp, Margaret A.
DOI：
10.1158/1078-0432.ccr-09-1339
发表时间：
2009-10-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Ansell SM;Hurvitz SA;Koenig PA;LaPlant BR;Kabat BF;Fernando D;Habermann TM;Inwards DJ;Verma M;Yamada R;Erlichman C;Lowy I;Timmerman JM
通讯作者：
Timmerman JM
DOI：
10.1158/1078-0432.ccr-13-0855
发表时间：
2013-07-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Chen BJ;Chapuy B;Ouyang J;Sun HH;Roemer MG;Xu ML;Yu H;Fletcher CD;Freeman GJ;Shipp MA;Rodig SJ
通讯作者：
Rodig SJ
影响因子：
64.8
作者：
Herbst RS;Soria JC;Kowanetz M;Fine GD;Hamid O;Gordon MS;Sosman JA;McDermott DF;Powderly JD;Gettinger SN;Kohrt HE;Horn L;Lawrence DP;Rost S;Leabman M;Xiao Y;Mokatrin A;Koeppen H;Hegde PS;Mellman I;Chen DS;Hodi FS
通讯作者：
Hodi FS
影响因子：
11.5
作者：
Berger, Raanan;Rotem-Yehudar, Rinat;Nagler, Arnon
通讯作者：
Nagler, Arnon